ContraFect Corp (NASDAQ:CFRX) was the recipient of a significant drop in short interest during the month of September. As of September 30th, there was short interest totalling 146,800 shares, a drop of 60.7% from the August 30th total of 374,000 shares. Approximately 0.3% of the shares of the company are short sold. Based on an average daily volume of 245,100 shares, the days-to-cover ratio is presently 0.6 days.
Shares of NASDAQ:CFRX traded down $0.01 during trading on Friday, hitting $0.29. The stock had a trading volume of 550,311 shares, compared to its average volume of 177,262. ContraFect has a 12-month low of $0.27 and a 12-month high of $2.63. The stock has a market capitalization of $23.02 million, a price-to-earnings ratio of -0.78 and a beta of 0.15. The company has a quick ratio of 4.15, a current ratio of 4.15 and a debt-to-equity ratio of 0.37. The stock has a 50-day simple moving average of $0.37 and a two-hundred day simple moving average of $0.45.
ContraFect (NASDAQ:CFRX) last announced its quarterly earnings data on Friday, August 9th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.09). As a group, sell-side analysts forecast that ContraFect will post -0.34 earnings per share for the current year.
Several large investors have recently made changes to their positions in the company. Oracle Investment Management Inc. raised its stake in shares of ContraFect by 13.1% in the second quarter. Oracle Investment Management Inc. now owns 6,356,649 shares of the biotechnology company’s stock worth $3,242,000 after purchasing an additional 735,450 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of ContraFect in the second quarter worth about $343,000. Trellus Management Company LLC purchased a new position in ContraFect during the second quarter valued at approximately $295,000. Finally, Hartwell J M Limited Partnership raised its position in ContraFect by 42.9% during the third quarter. Hartwell J M Limited Partnership now owns 200,000 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 60,000 shares in the last quarter. Hedge funds and other institutional investors own 34.86% of the company’s stock.
Several research analysts have recently issued reports on CFRX shares. Maxim Group restated a “buy” rating and issued a $2.00 price objective on shares of ContraFect in a research note on Friday, October 4th. ValuEngine upgraded ContraFect from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st.
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Recommended Story: Net Margin
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.